1、Acknowledges the growing virulence of C.difficileCaptures Klebsiella,Enterobacter,and other resistant species including E.coli and Proteus sp.Source:National Nosocomial Infections Surveillance(NNIS)Systemp0.001p0.001Kollef et al.Chest 1999;115:462-74N=655 ICU patients with infection169/655(25.8%)rec
2、eived inadequate therapy479 patients:165 MSSA,121 MRSA,193 controlsEngemann JJ,et al.CID 2003;36:592-8An economic analysis of the Chicago Antimicrobial Resistant Project dataset188/1391 patients(13.5%)with ARIRoberts RP et al.Clin Infect Dis 2009;49:1175-84Time above MICArea Under the Curve(AUC/MIC)
3、Peak(Peak/MIC)MICTimeDrug ConcentrationPAEBratu,AAC,2005;Quale,CID,2004;Leavitt,ACC,2007Reddy,ACC in printObjective to evaluate steady-state kinetics and pharmacodynamics of meropenem 500mg every 6,8,and 12 hours,based upon patient renal function.Patients were grouped based upon their renal functionas to which dose and interval they received based upon the following table Cheatham,S.C.Steady-State Pharmacokinetics and Pharmacodynamics of Meropenem in Hospitalized Patients.Pharmacotherapy 2008.28(6):691-698.
